We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bovie Medical Corp. | AMEX:BVX | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.48 | 0.00 | 01:00:00 |
|
|
|
|
|
|
ý
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the fiscal year ended December 31, 2017
|
|
or
|
|
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from _____ to _____
|
Commission File Number: 0-12183
|
|
BOVIE MEDICAL CORPORATION
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
11-2644611
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
Title of each Class
|
|
Name of each Exchange on which registered
|
Common Stock, $.001 Par Value
|
|
NYSE MKT Market
|
|
|
|
|
|
|
Part I
|
|
|
|
Page
|
Item 1
|
|
|
||
Item 1A
|
|
|
||
Item 1B
|
|
|
||
Item 2
|
|
|
||
Item 3
|
|
|
||
Item 4
|
|
|
||
|
|
|
|
|
Part II
|
|
|
|
|
Item 5
|
|
|
||
Item 6
|
|
|
||
Item 7
|
|
|
||
Item 7A
|
|
|
||
Item 8
|
|
|
||
Item 9
|
|
|
||
Item 9A
|
|
|
||
Item 9B
|
|
|
||
|
|
|
|
|
Part III
|
|
|
|
|
Item 10
|
|
|
||
Item 11
|
|
|
||
Item 12
|
|
|
||
Item 13
|
|
|
||
Item 14
|
|
|
||
|
|
|
|
|
Part IV
|
|
|
|
|
Item 15
|
|
|
||
Signatures
|
|
|
|
|
•
|
changes in general economic, business or demographic conditions or trends in the U.S. or throughout the world or changes in the political environment, including changes in GDP, interest rates and inflation;
|
•
|
our ability to conclude a sufficient number of attractive growth projects, deploy growth capital in amounts consistent with our objectives in the prosecution of those and achieve targeted risk-adjusted returns on any growth project, including the commercialization of our J-Plasma technology;
|
•
|
the regulatory environment, including our ability to gain requisite approval from the Food and Drug Administration, and the ability to estimate compliance costs, comply with any changes thereto, rates implemented by regulators, and our relationships and rights under and contracts with governmental agencies and authorities;
|
•
|
disruptions or other extraordinary or force majeure events and the ability to insure against losses resulting from such events or disruptions;
|
•
|
sudden or extreme volatility in commodity prices;
|
•
|
changes in competitive dynamics affecting our business and the medical device industry as a whole;
|
•
|
technological innovations leading to increased competition in the medical device industry;
|
•
|
our ability to service, comply with the terms of and refinance at maturity our indebtedness, including due to dislocation in debt markets;
|
•
|
changes in healthcare policy;
|
•
|
our ability to make alternate arrangements to account for any disruptions or shutdowns that may affect suppliers’ facilities or the operations upon which our business is dependent;
|
•
|
our ability to implement operating and internal growth strategies;
|
•
|
environmental risks, including the impact of climate change and weather conditions;
|
•
|
the impact of weather events, including potentially hurricanes, tornadoes and/or seasonal extremes;
|
•
|
unplanned outages and/or failures of technical and mechanical systems;
|
•
|
changes in U.S. income tax laws;
|
•
|
work interruptions or other labor stoppages;
|
•
|
A detailed description of the methods, facilities and controls used to manufacture the device and proposed labeling.
|
•
|
our product is determined to be ineffective or unsafe following approval and is removed from the market or we are required to perform additional research and development to further prove the safety and effectiveness of the product before re-entry into the market;
|
•
|
the regulatory approvals of our new products are delayed or we are required to conduct further research and development of our products prior to receiving regulatory approval;
|
•
|
we are unable to build a sales and marketing group to successfully launch and sell our new products;
|
•
|
we are unable to raise the additional funds needed to successfully develop and commercialize our products or acquire additional products for growth;
|
•
|
we are required to allocate available funds to litigation matters;
|
•
|
we are unable to manufacture the quantity of product needed in accordance with current good manufacturing practices to meet market demand, or at all;
|
•
|
competition from other products or technologies prevents or reduces market acceptance of our products;
|
•
|
we do not have and cannot obtain the intellectual property rights needed to manufacture or market our products without infringing on another company’s patents; or
|
•
|
we are unsuccessful in defending against patent infringement or other intellectual property rights, claims that could be brought against us, our products or technologies;
|
|
2017
|
|
2016
|
||||||||||||
|
High
|
|
Low
|
|
High
|
|
Low
|
||||||||
4th Quarter
|
$
|
4.29
|
|
|
$
|
2.54
|
|
|
$
|
5.55
|
|
|
$
|
3.50
|
|
3rd Quarter
|
3.48
|
|
|
2.17
|
|
|
5.21
|
|
|
1.68
|
|
||||
2nd Quarter
|
2.83
|
|
|
1.87
|
|
|
1.97
|
|
|
1.56
|
|
||||
1st Quarter
|
3.95
|
|
|
2.53
|
|
|
2.44
|
|
|
1.60
|
|
|
Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights
(a) |
|
Weighted Average Exercise Price of Outstanding Options, Warrants and Rights
(b) |
|
Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column (a))
(c) |
||||
Equity compensation plans approved by security holders
|
2,129,674
|
|
|
$
|
2.86
|
|
|
2,280,578
|
|
Equity compensation plans not approved by security holders
(1)
|
2,730,482
|
|
|
$
|
3.11
|
|
|
—
|
|
Total
|
4,860,157
|
|
|
$
|
3.00
|
|
|
2,280,578
|
|
|
December 31,
|
|||||||||||||
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|||||
Bovie Medical Corporation
|
100.00
|
|
|
171.16
|
|
|
97.67
|
|
|
166.97
|
|
|
120.93
|
|
S&P 500 Index
|
100.00
|
|
|
111.39
|
|
|
110.58
|
|
|
121.12
|
|
|
144.64
|
|
S&P 500 Health Care Index
|
100.00
|
|
|
123.3
|
|
|
129.72
|
|
|
124.07
|
|
|
148.89
|
|
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
||||||||||
Sales
|
$
|
38,883
|
|
|
$
|
36,627
|
|
|
$
|
29,520
|
|
|
$
|
27,681
|
|
|
$
|
23,660
|
|
Cost of sales
|
19,122
|
|
|
18,712
|
|
|
16,963
|
|
|
18,689
|
|
|
14,462
|
|
|||||
Gross profit
|
19,761
|
|
|
17,915
|
|
|
12,557
|
|
|
8,992
|
|
|
9,198
|
|
|||||
Other costs and expenses:
|
|
|
|
|
|
|
|
|
|
||||||||||
Research and development
|
2,455
|
|
|
2,618
|
|
|
2,160
|
|
|
1,416
|
|
|
1,260
|
|
|||||
Professional services
|
1,771
|
|
|
1,486
|
|
|
1,484
|
|
|
1,016
|
|
|
1,835
|
|
|||||
Salaries and related costs
|
7,906
|
|
|
9,038
|
|
|
7,482
|
|
|
5,723
|
|
|
3,992
|
|
|||||
Selling, general and administrative
|
11,370
|
|
|
8,565
|
|
|
8,417
|
|
|
6,686
|
|
|
5,777
|
|
|||||
Severance and related expense
|
1,524
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Total other costs and expenses
|
25,026
|
|
|
21,707
|
|
|
19,543
|
|
|
14,841
|
|
|
12,864
|
|
|||||
Loss from operations
|
(5,265
|
)
|
|
(3,792
|
)
|
|
(6,986
|
)
|
|
(5,849
|
)
|
|
(3,666
|
)
|
|||||
Interest expense, net
|
(136
|
)
|
|
(158
|
)
|
|
(158
|
)
|
|
(151
|
)
|
|
(237
|
)
|
|||||
Investor warrants issuance cost
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(664
|
)
|
|||||
Fee associated with refinance
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(543
|
)
|
|||||
Change in fair value of derivative liabilities
|
183
|
|
|
64
|
|
|
1,799
|
|
|
(7,285
|
)
|
|
(842
|
)
|
|||||
Total other income (loss), net
|
47
|
|
|
(94
|
)
|
|
1,641
|
|
|
(7,436
|
)
|
|
(2,286
|
)
|
|||||
Loss before income taxes
|
(5,218
|
)
|
|
(3,886
|
)
|
|
(5,345
|
)
|
|
(13,285
|
)
|
|
(5,952
|
)
|
|||||
Income tax (benefit) expense
|
(156
|
)
|
|
64
|
|
|
25
|
|
|
3,997
|
|
|
(1,613
|
)
|
|||||
Net loss
|
$
|
(5,062
|
)
|
|
$
|
(3,950
|
)
|
|
$
|
(5,370
|
)
|
|
$
|
(17,282
|
)
|
|
$
|
(4,339
|
)
|
Accretion on convertible preferred stock
|
—
|
|
|
—
|
|
|
(222
|
)
|
|
(932
|
)
|
|
(39
|
)
|
|||||
Gain on conversion of warrants and preferred shares, net
|
—
|
|
|
—
|
|
|
13,956
|
|
|
—
|
|
|
—
|
|
|||||
Deemed dividend on conversion beneficial conversion feature
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(2,616
|
)
|
|||||
Net (loss) income attributable to common shareholders
|
$
|
(5,062
|
)
|
|
$
|
(3,950
|
)
|
|
$
|
8,364
|
|
|
$
|
(18,214
|
)
|
|
$
|
(6,994
|
)
|
|
|
|
|
|
|
|
|
|
|
||||||||||
(Loss) income per share attributable to common shareholders
|
|
|
|
|
|
|
|
|
|
||||||||||
Basic
|
$
|
(0.16
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
0.34
|
|
|
$
|
(1.03
|
)
|
|
$
|
(0.40
|
)
|
Diluted
|
$
|
(0.17
|
)
|
|
$
|
(0.15
|
)
|
|
$
|
0.24
|
|
|
$
|
(1.03
|
)
|
|
$
|
(0.40
|
)
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Balance Sheet Information:
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash and restricted cash
|
$
|
10,668
|
|
|
$
|
15,235
|
|
|
$
|
12,644
|
|
|
$
|
6,632
|
|
|
$
|
7,924
|
|
Working capital
|
$
|
16,574
|
|
|
$
|
21,267
|
|
|
$
|
17,921
|
|
|
$
|
11,599
|
|
|
$
|
16,910
|
|
Total assets
|
$
|
30,988
|
|
|
$
|
35,110
|
|
|
$
|
31,448
|
|
|
$
|
24,833
|
|
|
$
|
33,176
|
|
Long-term liabilities
|
$
|
2,983
|
|
|
$
|
3,615
|
|
|
$
|
3,923
|
|
|
$
|
16,373
|
|
|
$
|
8,934
|
|
Total stockholders' equity
|
$
|
22,032
|
|
|
$
|
26,223
|
|
|
$
|
23,404
|
|
|
$
|
1,504
|
|
|
$
|
19,071
|
|
|
Year Ended
December 31, |
|
|
|
Year Ended
December 31, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2016
|
|
2015
|
|
Change
|
||||||||||
Sales by Reportable Segment
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Core
|
$
|
28,649
|
|
|
$
|
27,808
|
|
|
3.0
|
%
|
|
$
|
27,808
|
|
|
$
|
26,098
|
|
|
6.6
|
%
|
OEM
|
2,598
|
|
|
5,328
|
|
|
(51.2
|
)%
|
|
5,328
|
|
|
2,116
|
|
|
151.8
|
%
|
||||
Advanced Energy
|
7,636
|
|
|
3,491
|
|
|
118.7
|
%
|
|
3,491
|
|
|
1,306
|
|
|
167.3
|
%
|
||||
Total
|
$
|
38,883
|
|
|
$
|
36,627
|
|
|
6.2
|
%
|
|
$
|
36,627
|
|
|
$
|
29,520
|
|
|
24.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Sales by Product Line
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Electrosurgical
|
$
|
25,727
|
|
|
$
|
20,901
|
|
|
23.1
|
%
|
|
$
|
20,901
|
|
|
$
|
17,558
|
|
|
19.0
|
%
|
Cauteries
|
7,141
|
|
|
7,101
|
|
|
0.6
|
%
|
|
7,101
|
|
|
6,886
|
|
|
3.1
|
%
|
||||
Lighting
|
2,435
|
|
|
2,710
|
|
|
(10.1
|
)%
|
|
2,710
|
|
|
2,477
|
|
|
9.4
|
%
|
||||
Other
|
3,580
|
|
|
5,915
|
|
|
(39.5
|
)%
|
|
5,915
|
|
|
2,599
|
|
|
127.6
|
%
|
||||
Total
|
$
|
38,883
|
|
|
$
|
36,627
|
|
|
6.2
|
%
|
|
$
|
36,627
|
|
|
$
|
29,520
|
|
|
24.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Sales by Domestic and International
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Domestic
|
$
|
33,147
|
|
|
$
|
32,050
|
|
|
3.4
|
%
|
|
$
|
32,050
|
|
|
$
|
24,540
|
|
|
30.6
|
%
|
International
|
5,736
|
|
|
4,577
|
|
|
25.3
|
%
|
|
4,577
|
|
|
4,980
|
|
|
(8.1
|
)%
|
||||
Total
|
$
|
38,883
|
|
|
$
|
36,627
|
|
|
6.2
|
%
|
|
$
|
36,627
|
|
|
$
|
29,520
|
|
|
24.1
|
%
|
|
Year Ended
December 31, |
|
|
|
Year Ended
December 31, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2016
|
|
2015
|
|
Change
|
||||||||||
Cost of sales
|
$
|
19,122
|
|
|
$
|
18,712
|
|
|
2.2
|
%
|
|
$
|
18,712
|
|
|
$
|
16,963
|
|
|
10.3
|
%
|
Percentage of sales
|
49.2
|
%
|
|
51.1
|
%
|
|
|
|
|
51.1
|
%
|
|
57.5
|
%
|
|
|
|
Gross profit
|
$
|
19,761
|
|
|
$
|
17,915
|
|
|
10.3
|
%
|
|
$
|
17,915
|
|
|
$
|
12,557
|
|
|
42.7
|
%
|
Percentage of sales
|
50.8
|
%
|
|
48.9
|
%
|
|
1.9
|
%
|
|
48.9
|
%
|
|
42.5
|
%
|
|
6.4
|
%
|
|
Year Ended
December 31, |
|
|
|
Year Ended
December 31, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2016
|
|
2015
|
|
Change
|
||||||||||
Research and Development expense
|
$
|
2,455
|
|
|
$
|
2,618
|
|
|
(6.2
|
)%
|
|
$
|
2,618
|
|
|
$
|
2,160
|
|
|
21.2
|
%
|
Percentage of sales
|
6.3
|
%
|
|
7.1
|
%
|
|
|
|
|
7.1
|
%
|
|
7.3
|
%
|
|
|
|
|
Year Ended
December 31, |
|
|
|
Year Ended
December 31, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2016
|
|
2015
|
|
Change
|
||||||||||
Professional services expense
|
$
|
1,771
|
|
|
$
|
1,486
|
|
|
19.2
|
%
|
|
$
|
1,486
|
|
|
$
|
1,484
|
|
|
0.1
|
%
|
Percentage of sales
|
4.6
|
%
|
|
4.1
|
%
|
|
|
|
|
4.1
|
%
|
|
5.0
|
%
|
|
|
|
|
Year Ended
December 31, |
|
|
|
Year Ended
December 31, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2016
|
|
2015
|
|
Change
|
||||||||||
Salaries and related expenses
|
$
|
7,906
|
|
|
$
|
9,038
|
|
|
(12.5
|
)%
|
|
$
|
9,038
|
|
|
$
|
7,482
|
|
|
20.8
|
%
|
Percentage of sales
|
20.3
|
%
|
|
24.7
|
%
|
|
|
|
|
24.7
|
%
|
|
25.3
|
%
|
|
|
|
|
Year Ended
December 31, |
|
|
|
Year Ended
December 31, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2016
|
|
2015
|
|
Change
|
||||||||||
SG&A Expense
|
$
|
11,370
|
|
|
$
|
8,565
|
|
|
32.7
|
%
|
|
$
|
8,565
|
|
|
$
|
8,417
|
|
|
1.8
|
%
|
Percentage of sales
|
29.2
|
%
|
|
23.4
|
%
|
|
|
|
|
23.4
|
%
|
|
28.5
|
%
|
|
|
|
|
Year Ended
December 31, |
|
|
|
Year Ended
December 31, |
|
|
||||||||||||||
(In thousands)
|
2017
|
|
2016
|
|
Change
|
|
2016
|
|
2015
|
|
Change
|
||||||||||
Interest expense, net
|
$
|
(136
|
)
|
|
$
|
(158
|
)
|
|
(13.9
|
)%
|
|
$
|
(158
|
)
|
|
$
|
(158
|
)
|
|
—
|
%
|
Percentage of sales
|
(0.3
|
)%
|
|
(0.4
|
)%
|
|
|
|
|
(0.4
|
)%
|
|
(0.5
|
)%
|
|
|
|
||||
Change in fair value of derivative liabilities
|
$
|
183
|
|
|
$
|
64
|
|
|
185.9
|
%
|
|
$
|
64
|
|
|
$
|
1,799
|
|
|
(96.4
|
)%
|
Percentage of sales
|
0.5
|
%
|
|
0.2
|
%
|
|
|
|
0.2
|
%
|
|
6.1
|
%
|
|
|
(In thousands)
|
|
||
2018
|
$
|
247
|
|
2019
|
2,541
|
|
|
Total
|
$
|
2,788
|
|
|
Page
|
|
December 31,
2017 |
|
December 31,
2016 |
||||
ASSETS
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
9,949
|
|
|
$
|
14,456
|
|
Restricted cash
|
719
|
|
|
779
|
|
||
Trade accounts receivable, net of allowance of $204 and $118
|
4,857
|
|
|
4,733
|
|
||
Inventories, net
|
6,526
|
|
|
6,158
|
|
||
Prepaid expenses and other current assets
|
496
|
|
|
413
|
|
||
Total current assets
|
22,547
|
|
|
26,539
|
|
||
Property and equipment, net
|
6,408
|
|
|
6,449
|
|
||
Brand name and trademark
|
1,510
|
|
|
1,510
|
|
||
Purchased technology and license rights, net
|
179
|
|
|
215
|
|
||
Goodwill
|
185
|
|
|
185
|
|
||
Deposits
|
92
|
|
|
109
|
|
||
Other assets
|
67
|
|
|
103
|
|
||
Total assets
|
$
|
30,988
|
|
|
$
|
35,110
|
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
1,583
|
|
|
$
|
1,606
|
|
Accrued severance and related
|
1,242
|
|
|
—
|
|
||
Accrued payroll
|
447
|
|
|
419
|
|
||
Accrued vacation
|
74
|
|
|
404
|
|
||
Current portion of mortgage note payable
|
239
|
|
|
239
|
|
||
Accrued and other liabilities
|
2,388
|
|
|
2,604
|
|
||
Total current liabilities
|
5,973
|
|
|
5,272
|
|
||
Mortgage note payable, net of current portion
|
2,455
|
|
|
2,694
|
|
||
Note payable
|
140
|
|
|
140
|
|
||
Deferred rents
|
—
|
|
|
14
|
|
||
Deferred tax liability
|
368
|
|
|
564
|
|
||
Derivative liabilities
|
20
|
|
|
203
|
|
||
Total liabilities
|
8,956
|
|
|
8,887
|
|
||
Commitments and Contingencies (see Notes 9 and 11)
|
|
|
|
||||
|
|
|
|
||||
STOCKHOLDERS' EQUITY
|
|
|
|
||||
Series B convertible preferred stock, $0.001 par value; 3,588,139 authorized and zero issued and outstanding as of December 31, 2017 and 3,588,139 authorized and 975,639 issued and outstanding as of December 31, 2016, respectively
|
—
|
|
|
1
|
|
||
Common stock, $0.001 par value; 75,000,000 shares authorized; 33,021,170 issued and 32,878,091 outstanding as of December 31, 2017 and 40,000,000 shares authorized; 31,002,832 issued and 30,859,753 outstanding as of December 31, 2016, respectively
|
33
|
|
|
31
|
|
||
Additional paid-in capital
|
50,495
|
|
|
49,625
|
|
||
Accumulated deficit
|
(28,496
|
)
|
|
(23,434
|
)
|
||
Total stockholders' equity
|
22,032
|
|
|
26,223
|
|
||
Total liabilities and stockholders' equity
|
$
|
30,988
|
|
|
$
|
35,110
|
|
|
Year Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
Sales
|
$
|
38,883
|
|
|
$
|
36,627
|
|
|
$
|
29,520
|
|
Cost of sales
|
19,122
|
|
|
18,712
|
|
|
16,963
|
|
|||
Gross profit
|
19,761
|
|
|
17,915
|
|
|
12,557
|
|
|||
Other costs and expenses:
|
|
|
|
|
|
||||||
Research and development
|
2,455
|
|
|
2,618
|
|
|
2,160
|
|
|||
Professional services
|
1,771
|
|
|
1,486
|
|
|
1,484
|
|
|||
Salaries and related costs
|
7,906
|
|
|
9,038
|
|
|
7,482
|
|
|||
Selling, general and administrative
|
11,370
|
|
|
8,565
|
|
|
8,417
|
|
|||
Severance and related expense
|
1,524
|
|
|
—
|
|
|
—
|
|
|||
Total other costs and expenses
|
25,026
|
|
|
21,707
|
|
|
19,543
|
|
|||
Loss from operations
|
(5,265
|
)
|
|
(3,792
|
)
|
|
(6,986
|
)
|
|||
Interest expense, net
|
(136
|
)
|
|
(158
|
)
|
|
(158
|
)
|
|||
Change in fair value of derivative liabilities
|
183
|
|
|
64
|
|
|
1,799
|
|
|||
Total other income (loss), net
|
47
|
|
|
(94
|
)
|
|
1,641
|
|
|||
Loss before income taxes
|
(5,218
|
)
|
|
(3,886
|
)
|
|
(5,345
|
)
|
|||
Income tax (benefit) expense
|
(156
|
)
|
|
64
|
|
|
25
|
|
|||
Net loss
|
$
|
(5,062
|
)
|
|
$
|
(3,950
|
)
|
|
$
|
(5,370
|
)
|
Accretion on convertible preferred stock
|
—
|
|
|
—
|
|
|
(222
|
)
|
|||
Gain on conversion of warrants and preferred shares, net
|
—
|
|
|
—
|
|
|
13,956
|
|
|||
Net (loss) income attributable to common shareholders
|
$
|
(5,062
|
)
|
|
$
|
(3,950
|
)
|
|
$
|
8,364
|
|
|
|
|
|
|
|
||||||
(Loss) income per share attributable to common shareholders
|
|
|
|
|
|
||||||
Basic
|
$
|
(0.16
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
0.34
|
|
Diluted
|
$
|
(0.17
|
)
|
|
$
|
(0.15
|
)
|
|
$
|
0.24
|
|
|
|
|
|
|
|
||||||
Weighted average number of shares outstanding - basic
|
31,420
|
|
|
27,433
|
|
|
24,333
|
|
|||
Weighted average number of shares outstanding - dilutive
|
31,427
|
|
|
27,449
|
|
|
27,747
|
|
|
Preferred Stock
|
|
Common Stock
|
|
|
|
|
|
|
||||||||||||||||
|
Shares
|
|
Par Value
|
|
Shares
|
|
Par Value
|
|
Additional Paid-In Capital
|
|
Accumulated Deficit
|
|
Total
|
||||||||||||
Balance
December 31, 2014 |
—
|
|
|
$
|
—
|
|
|
17,852
|
|
|
$
|
18
|
|
|
$
|
29,334
|
|
|
$
|
(27,848
|
)
|
|
$
|
1,504
|
|
Options exercised
|
—
|
|
|
—
|
|
|
98
|
|
|
—
|
|
|
220
|
|
|
—
|
|
|
220
|
|
|||||
Warrants exercised
|
—
|
|
|
—
|
|
|
739
|
|
|
—
|
|
|
1,519
|
|
|
—
|
|
|
1,519
|
|
|||||
Issuance of common stock
|
—
|
|
|
—
|
|
|
5,219
|
|
|
5
|
|
|
11,526
|
|
|
—
|
|
|
11,531
|
|
|||||
Conversion of Series A preferred stock and common warrants to Series B preferred stock
|
3,588
|
|
|
4
|
|
|
—
|
|
|
—
|
|
|
(40
|
)
|
|
13,956
|
|
|
13,920
|
|
|||||
Conversion of Series B convertible preferred to common stock
|
(1,612
|
)
|
|
(2
|
)
|
|
3,225
|
|
|
4
|
|
|
(2
|
)
|
|
—
|
|
|
—
|
|
|||||
Stock based compensation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
575
|
|
|
—
|
|
|
575
|
|
|||||
Stock swap to acquire options and warrants
|
—
|
|
|
—
|
|
|
(81
|
)
|
|
—
|
|
|
(273
|
)
|
|
—
|
|
|
(273
|
)
|
|||||
Accretion on convertible preferred stock
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(222
|
)
|
|
(222
|
)
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(5,370
|
)
|
|
(5,370
|
)
|
|||||
Balance
December 31, 2015 |
1,976
|
|
|
$
|
2
|
|
|
27,052
|
|
|
$
|
27
|
|
|
$
|
42,859
|
|
|
$
|
(19,484
|
)
|
|
$
|
23,404
|
|
Options exercised
|
—
|
|
|
—
|
|
|
36
|
|
|
—
|
|
|
130
|
|
|
—
|
|
|
130
|
|
|||||
Warrants exercised
|
—
|
|
|
—
|
|
|
293
|
|
|
—
|
|
|
698
|
|
|
—
|
|
|
698
|
|
|||||
Issuance of common stock
|
—
|
|
|
—
|
|
|
1,625
|
|
|
2
|
|
|
5,828
|
|
|
—
|
|
|
5,830
|
|
|||||
Conversion of Series B convertible preferred to common stock
|
(1,000
|
)
|
|
(1
|
)
|
|
2,000
|
|
|
2
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|||||
Stock based compensation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
809
|
|
|
—
|
|
|
809
|
|
|||||
Stock swap to acquire options and warrants
|
—
|
|
|
—
|
|
|
(146
|
)
|
|
—
|
|
|
(698
|
)
|
|
—
|
|
|
(698
|
)
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(3,950
|
)
|
|
(3,950
|
)
|
|||||
Balance
December 31, 2016 |
976
|
|
|
$
|
1
|
|
|
30,860
|
|
|
$
|
31
|
|
|
$
|
49,625
|
|
|
$
|
(23,434
|
)
|
|
$
|
26,223
|
|
Options exercised
|
—
|
|
|
—
|
|
|
177
|
|
|
—
|
|
|
427
|
|
|
—
|
|
|
427
|
|
|||||
Warrants exercised
|
—
|
|
|
—
|
|
|
54
|
|
|
—
|
|
|
130
|
|
|
—
|
|
|
130
|
|
|||||
Conversion of Series B convertible preferred to common stock
|
(976
|
)
|
|
(1
|
)
|
|
1,951
|
|
|
2
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|||||
Stock based compensation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
871
|
|
|
—
|
|
|
871
|
|
|||||
Stock swap to acquire options and warrants
|
—
|
|
|
—
|
|
|
(164
|
)
|
|
—
|
|
|
(557
|
)
|
|
—
|
|
|
(557
|
)
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(5,062
|
)
|
|
(5,062
|
)
|
|||||
Balance
December 31, 2017 |
—
|
|
|
$
|
—
|
|
|
32,878
|
|
|
$
|
33
|
|
|
$
|
50,495
|
|
|
$
|
(28,496
|
)
|
|
$
|
22,032
|
|
|
Year Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
Cash flows from operating activities
|
|
|
|
|
|
||||||
Net loss
|
$
|
(5,062
|
)
|
|
$
|
(3,950
|
)
|
|
$
|
(5,370
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
||||||
Depreciation and amortization
|
696
|
|
|
734
|
|
|
812
|
|
|||
Provision for inventory obsolescence
|
502
|
|
|
178
|
|
|
157
|
|
|||
Gain on disposal of property and equipment, net
|
5
|
|
|
21
|
|
|
21
|
|
|||
Stock based compensation
|
871
|
|
|
809
|
|
|
575
|
|
|||
Change in fair value of derivative liabilities
|
(183
|
)
|
|
(64
|
)
|
|
(1,799
|
)
|
|||
Provision for allowance for doubtful accounts
|
179
|
|
|
84
|
|
|
96
|
|
|||
Provision (benefit) for deferred taxes
|
(196
|
)
|
|
25
|
|
|
(25
|
)
|
|||
Changes in current assets and liabilities:
|
|
|
|
|
|
||||||
Trade receivables
|
(303
|
)
|
|
(1,894
|
)
|
|
(1,029
|
)
|
|||
Prepaid expenses
|
(83
|
)
|
|
103
|
|
|
286
|
|
|||
Inventories
|
(870
|
)
|
|
(379
|
)
|
|
(102
|
)
|
|||
Deposits and other assets
|
53
|
|
|
341
|
|
|
228
|
|
|||
Accounts payable
|
(23
|
)
|
|
392
|
|
|
(189
|
)
|
|||
Accrued severance and related
|
1,242
|
|
|
—
|
|
|
—
|
|
|||
Accrued and other liabilities
|
(532
|
)
|
|
763
|
|
|
553
|
|
|||
Net cash used in operating activities
|
(3,704
|
)
|
|
(2,837
|
)
|
|
(5,786
|
)
|
|||
Cash flows from investing activities
|
|
|
|
|
|
||||||
Purchases of technology, property and equipment
|
(624
|
)
|
|
(286
|
)
|
|
(421
|
)
|
|||
Acquisition of Bovie Bulgaria, net of cash acquired
|
—
|
|
|
—
|
|
|
(500
|
)
|
|||
Net cash used in investing activities
|
(624
|
)
|
|
(286
|
)
|
|
(921
|
)
|
|||
Cash flows from financing activities
|
|
|
|
|
|
||||||
Proceeds from stock options/warrants exercised
|
—
|
|
|
124
|
|
|
1,427
|
|
|||
Change in restricted cash
|
60
|
|
|
60
|
|
|
60
|
|
|||
Repayment of mortgage note payable
|
(239
|
)
|
|
(240
|
)
|
|
(239
|
)
|
|||
Proceeds from issuance of common shares, net
|
—
|
|
|
5,830
|
|
|
11,531
|
|
|||
Net cash (used in) provided by financing activities
|
(179
|
)
|
|
5,774
|
|
|
12,779
|
|
|||
Net change in cash and cash equivalents
|
(4,507
|
)
|
|
2,651
|
|
|
6,072
|
|
|||
Cash and cash equivalents, beginning of period
|
14,456
|
|
|
11,805
|
|
|
5,733
|
|
|||
Cash and cash equivalents, end of period
|
$
|
9,949
|
|
|
$
|
14,456
|
|
|
$
|
11,805
|
|
|
|
|
|
|
|
||||||
Cash paid for:
|
|
|
|
|
|
||||||
Interest paid
|
$
|
136
|
|
|
$
|
158
|
|
|
$
|
158
|
|
|
|
|
|
|
|
||||||
Non cash investing activities:
|
|
|
|
|
|
||||||
Note payable for acquisitions
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
140
|
|
Cashless exercise of stock options/warrants
|
$
|
557
|
|
|
$
|
698
|
|
|
$
|
272
|
|
(In thousands)
|
December 31,
2017 |
|
December 31,
2016 |
||||
Raw materials
|
$
|
5,163
|
|
|
$
|
4,521
|
|
Finished goods
|
3,276
|
|
|
3,048
|
|
||
Gross inventories
|
8,439
|
|
|
7,569
|
|
||
Less: reserve for obsolescence
|
(1,913
|
)
|
|
(1,411
|
)
|
||
Inventories, net
|
$
|
6,526
|
|
|
$
|
6,158
|
|
•
|
The majority of our sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.
|
•
|
Product returns are only accepted at our discretion and in accordance with our “Returned Goods Policy”. Historically, the level of product returns has not been significant. We accrue for sales returns, rebates and allowances based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.
|
•
|
Our terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.
|
•
|
Amounts billed to customers related to shipping and handling charges are included in sales. Shipping and handling costs included in cost of sales were approximately
$0.2 million
,
$0.2 million
and
$0.1 million
in
2017
,
2016
and
2015
, respectively.
|
(In thousands)
|
December 31,
2017 |
|
December 31,
2016 |
||||
Trade accounts receivable
|
$
|
5,061
|
|
|
$
|
4,851
|
|
Less: allowance for doubtful accounts
|
(204
|
)
|
|
(118
|
)
|
||
Trade accounts receivable, net
|
4,857
|
|
|
4,733
|
|
(In thousands)
|
December 31,
2017 |
|
December 31,
2016 |
||||
Land
|
$
|
1,600
|
|
|
$
|
1,600
|
|
Machinery and equipment
|
3,231
|
|
|
3,775
|
|
||
Building and improvements
|
4,512
|
|
|
4,237
|
|
||
Furniture and fixtures
|
1,947
|
|
|
2,194
|
|
||
Leasehold improvements
|
—
|
|
|
12
|
|
||
Molds
|
1,829
|
|
|
1,900
|
|
||
Total property, plant and equipment
|
13,119
|
|
|
13,718
|
|
||
Less: accumulated depreciation
|
(6,711
|
)
|
|
(7,269
|
)
|
||
Net property, plant and equipment
|
$
|
6,408
|
|
|
$
|
6,449
|
|
(In thousands)
|
December 31,
2017 |
|
December 31,
2016 |
||||
Brand name and trademark (life indefinite)
|
$
|
1,510
|
|
|
$
|
1,510
|
|
|
|
|
|
||||
Purchased technology (5-17 year lives)
|
$
|
1,513
|
|
|
$
|
1,441
|
|
Less: accumulated amortization
|
(1,334
|
)
|
|
(1,226
|
)
|
||
Purchased technology, net
|
$
|
179
|
|
|
$
|
215
|
|
|
|
|
|
||||
Goodwill
|
$
|
185
|
|
|
$
|
185
|
|
|
Year Ended December 31,
|
||||||||||
(in thousands, except per share data)
|
2017
|
|
2016
|
|
2015
|
||||||
Numerator:
|
|
|
|
|
|
||||||
Net (loss) income available to common shareholders
|
$
|
(5,062
|
)
|
|
$
|
(3,950
|
)
|
|
$
|
8,364
|
|
Effect of dilutive securities:
|
|
|
|
|
|
||||||
Derivative liability - warrants
|
(183
|
)
|
|
(64
|
)
|
|
(1,799
|
)
|
|||
Accretion on convertible preferred stock
|
—
|
|
|
—
|
|
|
222
|
|
|||
Numerator for dilutive (loss) income per common share
|
(5,245
|
)
|
|
(4,014
|
)
|
|
6,787
|
|
|||
|
|
|
|
|
|
||||||
Denominator:
|
|
|
|
|
|
||||||
Weighted average shares used to compute basic (loss) income
per common share |
31,420
|
|
|
27,433
|
|
|
24,333
|
|
|||
Effect of dilutive securities:
|
|
|
|
|
|
||||||
Derivative liability - warrants
|
7
|
|
|
16
|
|
|
28
|
|
|||
Convertible preferred stock
|
—
|
|
|
—
|
|
|
3,137
|
|
|||
Stock options
|
—
|
|
|
—
|
|
|
249
|
|
|||
Denominator for dilutive (loss) income per common share
|
31,427
|
|
|
27,449
|
|
|
27,747
|
|
|||
|
|
|
|
|
|
||||||
Basic (loss) income per common share
|
$
|
(0.16
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
0.34
|
|
Diluted (loss) income per common share
|
$
|
(0.17
|
)
|
|
$
|
(0.15
|
)
|
|
$
|
0.24
|
|
(in thousands)
|
2013
Placement Agent Warrants
|
||
Balance, December 31, 2015
|
$
|
267
|
|
Exercise of warrants
|
(698
|
)
|
|
Change in fair value
|
634
|
|
|
Balance, December 31, 2016
|
203
|
|
|
Exercise of warrants
|
(130
|
)
|
|
Change in fair value
|
(53
|
)
|
|
Balance, December 31, 2017
|
$
|
20
|
|
(In thousands)
|
Long-term debt
|
||
2018
|
$
|
239
|
|
2019
|
2,455
|
|
|
Total
|
$
|
2,694
|
|
(In thousands)
|
December 31,
2017 |
|
December 31,
2016 |
||||
Deferred tax assets:
|
|
|
|
||||
Loss and credit carry-forwards
|
$
|
7,722
|
|
|
$
|
9,169
|
|
Stock-based compensation
|
549
|
|
|
519
|
|
||
Inventory Reserve
|
494
|
|
|
534
|
|
||
Other
|
178
|
|
|
263
|
|
||
Total deferred tax assets
|
8,943
|
|
|
10,485
|
|
||
Valuation allowance
|
(8,756
|
)
|
|
(10,185
|
)
|
||
Total deferred tax assets, net of valuation allowance
|
187
|
|
|
300
|
|
||
Deferred tax liabilities:
|
|
|
|
||||
State taxes (capital)
|
(17
|
)
|
|
(19
|
)
|
||
Property and equipment
|
(294
|
)
|
|
(459
|
)
|
||
Intangibles
|
(244
|
)
|
|
(386
|
)
|
||
Total deferred tax liabilities
|
(555
|
)
|
|
(864
|
)
|
||
Net deferred tax liabilities
|
$
|
(368
|
)
|
|
$
|
(564
|
)
|
|
Year Ended December 31,
|
|||||||
|
2017
|
|
2016
|
|
2015
|
|||
Federal tax provision
|
34.0
|
%
|
|
34.0
|
%
|
|
34.0
|
%
|
State taxes (net of federal benefit)
|
4.8
|
%
|
|
3.7
|
%
|
|
2.4
|
%
|
Warrant gains
|
0.4
|
%
|
|
31.4
|
%
|
|
(11.1
|
)%
|
Valuation allowance
|
28.9
|
%
|
|
(71.8
|
)%
|
|
(26.3
|
)%
|
Change in federal tax rate
|
(71.2
|
)%
|
|
—
|
%
|
|
—
|
%
|
Other
|
6.2
|
%
|
|
1.5
|
%
|
|
0.6
|
%
|
|
3.1
|
%
|
|
(1.2
|
)%
|
|
(0.4
|
)%
|
|
Number of options
|
|
Weighted average exercise price
|
|||
Outstanding at December 31, 2015
|
3,131,447
|
|
|
$
|
3.38
|
|
Granted
|
810,762
|
|
|
1.87
|
|
|
Exercised
|
(36,250
|
)
|
|
3.62
|
|
|
Canceled and forfeited
|
(153,750
|
)
|
|
3.69
|
|
|
Outstanding at December 31, 2016
|
3,752,209
|
|
|
$
|
3.04
|
|
Granted
|
1,728,000
|
|
|
3.09
|
|
|
Exercised
|
(176,750
|
)
|
|
2.41
|
|
|
Canceled and forfeited
|
(443,302
|
)
|
|
3.95
|
|
|
Outstanding at December 31, 2017
|
4,860,157
|
|
|
$
|
3.00
|
|
|
|
|
|
|||
Exercisable at December 31, 2017
|
2,627,722
|
|
|
$
|
3.46
|
|
|
Number of options
|
|
Weighted average grant date fair value
|
|||
Non-vested at December 31, 2016
|
1,745,506
|
|
|
$
|
1.25
|
|
Granted
|
1,728,000
|
|
|
1.82
|
|
|
Vested
|
(797,769
|
)
|
|
1.01
|
|
|
Forfeited
|
(443,302
|
)
|
|
1.95
|
|
|
Non-vested at December 31, 2017
|
2,232,435
|
|
|
1.40
|
|
|
2017 Grants
|
|
2016 Grants
|
|
2015 Grants
|
||||||
Option value
|
$1.73
|
-
|
$2.34
|
|
$0.80
|
-
|
$0.91
|
|
$0.90
|
-
|
$1.84
|
Risk-free rate
|
1.5%
|
-
|
1.9%
|
|
1.5%
|
-
|
1.8%
|
|
0.2%
|
|
1.6%
|
Expected dividend yield
|
—%
|
|
—%
|
|
—%
|
||||||
Expected volatility
|
62.1%
|
-
|
68.0%
|
|
49.5%
|
-
|
50.3%
|
|
53.0%
|
-
|
54.0%
|
Expected term (in years)
|
6
|
|
6
|
|
6
|
|
Year Ended December 31,
|
||||||||||
(In thousands)
|
2017
|
|
2016
|
|
2015
|
||||||
Cost of sales
|
$
|
—
|
|
|
$
|
2
|
|
|
$
|
3
|
|
Research and development
|
27
|
|
|
27
|
|
|
39
|
|
|||
Salaries and related costs
|
844
|
|
|
780
|
|
|
526
|
|
|||
Total
|
$
|
871
|
|
|
$
|
809
|
|
|
$
|
568
|
|
|
Year ended December 31, 2017
|
||||||||||||||||||
(In thousands)
|
Core
|
|
OEM
|
|
Advanced Energy
|
|
Corporate (Other)
|
|
Total
|
||||||||||
Sales
|
$
|
28,649
|
|
|
$
|
2,598
|
|
|
$
|
7,636
|
|
|
$
|
—
|
|
|
$
|
38,883
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Income (loss) from operations
|
8,620
|
|
|
1,353
|
|
|
(3,957
|
)
|
|
(11,281
|
)
|
|
(5,265
|
)
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Severance and related expense
|
—
|
|
|
—
|
|
|
—
|
|
|
1,524
|
|
|
1,524
|
|
|||||
Interest expense, net
|
—
|
|
|
—
|
|
|
—
|
|
|
(136
|
)
|
|
(136
|
)
|
|||||
Change in fair value of derivative liabilities
|
—
|
|
|
—
|
|
|
—
|
|
|
183
|
|
|
183
|
|
|||||
Income tax benefit
|
—
|
|
|
—
|
|
|
—
|
|
|
(156
|
)
|
|
(156
|
)
|
|||||
Depreciation and amortization
|
—
|
|
|
—
|
|
|
—
|
|
|
696
|
|
|
696
|
|
|
Year ended December 31, 2016
|
||||||||||||||||||
(In thousands)
|
Core
|
|
OEM
|
|
Advanced Energy
|
|
Corporate (Other)
|
|
Total
|
||||||||||
Sales
|
$
|
27,808
|
|
|
$
|
5,328
|
|
|
$
|
3,491
|
|
|
$
|
—
|
|
|
$
|
36,627
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Income (loss) from operations
|
7,600
|
|
|
3,045
|
|
|
(4,812
|
)
|
|
(9,625
|
)
|
|
(3,792
|
)
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Severance and related expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Interest expense, net
|
—
|
|
|
—
|
|
|
—
|
|
|
(158
|
)
|
|
(158
|
)
|
|||||
Change in fair value of derivative liabilities
|
—
|
|
|
—
|
|
|
—
|
|
|
64
|
|
|
64
|
|
|||||
Income tax expense
|
—
|
|
|
—
|
|
|
—
|
|
|
64
|
|
|
64
|
|
|||||
Depreciation and amortization
|
—
|
|
|
—
|
|
|
—
|
|
|
734
|
|
|
734
|
|
|
Year ended December 31, 2015
|
||||||||||||||||||
(In thousands)
|
Core
|
|
OEM
|
|
Advanced Energy
|
|
Corporate (Other)
|
|
Total
|
||||||||||
Sales
|
$
|
26,098
|
|
|
$
|
2,116
|
|
|
$
|
1,306
|
|
|
$
|
—
|
|
|
$
|
29,520
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Income (loss) from operations
|
5,690
|
|
|
1,524
|
|
|
(4,688
|
)
|
|
(9,512
|
)
|
|
(6,986
|
)
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Severance and related expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Interest expense, net
|
—
|
|
|
—
|
|
|
—
|
|
|
(158
|
)
|
|
(158
|
)
|
|||||
Change in fair value of derivative liabilities
|
—
|
|
|
—
|
|
|
—
|
|
|
1,799
|
|
|
1,799
|
|
|||||
Income tax expense
|
—
|
|
|
—
|
|
|
—
|
|
|
25
|
|
|
25
|
|
|||||
Depreciation and amortization
|
—
|
|
|
—
|
|
|
—
|
|
|
812
|
|
|
812
|
|
|
Year Ended December 31,
|
||||||||||
(In thousands)
|
2017
|
|
2016
|
|
2015
|
||||||
Sales by Product Line
|
|
|
|
|
|
||||||
Electrosurgical
|
$
|
25,727
|
|
|
$
|
20,901
|
|
|
$
|
17,558
|
|
Cauteries
|
7,141
|
|
|
7,101
|
|
|
6,886
|
|
|||
Lighting
|
2,435
|
|
|
2,710
|
|
|
2,477
|
|
|||
Other
|
3,580
|
|
|
5,915
|
|
|
2,599
|
|
|||
Total
|
$
|
38,883
|
|
|
$
|
36,627
|
|
|
$
|
29,520
|
|
|
Year Ended December 31,
|
||||||||||
(In thousands)
|
2017
|
|
2016
|
|
2015
|
||||||
Sales by Domestic and International
|
|
|
|
|
|
||||||
Domestic
|
$
|
33,147
|
|
|
$
|
32,050
|
|
|
$
|
24,540
|
|
International
|
5,736
|
|
|
4,577
|
|
|
4,980
|
|
|||
Total
|
$
|
38,883
|
|
|
$
|
36,627
|
|
|
$
|
29,520
|
|
(In thousands, except per share data)
|
First
Quarter |
|
Second
Quarter |
|
Third
Quarter |
|
Fourth
Quarter |
||||||||
Year ended December 31, 2017
|
|
|
|
|
|
|
|
||||||||
Sales
|
$
|
8,389
|
|
|
$
|
9,799
|
|
|
$
|
9,347
|
|
|
$
|
11,348
|
|
Gross profit
|
4,226
|
|
|
5,042
|
|
|
4,594
|
|
|
5,899
|
|
||||
Net loss attributable to common shareholders
|
(1,685
|
)
|
|
(1,308
|
)
|
|
(1,245
|
)
|
|
(824
|
)*
|
||||
Basic loss per common share
|
$
|
(0.05
|
)
|
|
$
|
(0.04
|
)
|
|
$
|
(0.04
|
)
|
|
$
|
(0.03
|
)
|
|
|
|
|
|
|
|
|
||||||||
Year ended December 31, 2016
|
|
|
|
|
|
|
|
||||||||
Sales
|
$
|
7,775
|
|
|
$
|
9,295
|
|
|
$
|
10,063
|
|
|
$
|
9,494
|
|
Gross profit
|
3,323
|
|
|
4,700
|
|
|
5,062
|
|
|
4,830
|
|
||||
Net loss attributable to common shareholders
|
(1,944
|
)
|
|
(519
|
)
|
|
(964
|
)
|
|
(523
|
)
|
||||
Basic loss per common share
|
$
|
(0.07
|
)
|
|
$
|
(0.02
|
)
|
|
$
|
(0.04
|
)
|
|
$
|
(0.02
|
)
|
•
|
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
|
•
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
|
•
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
|
Name
|
|
Age
|
|
Position
|
|
Director Since
|
Charles D. Goodwin
|
|
52
|
|
Chief Executive Officer and Director
|
|
December 2017
|
Jay D. Ewers
|
|
57
|
|
Chief Financial Officer, Treasurer and Secretary
|
|
N/A
|
J. Robert Saron
|
|
65
|
|
President, Chief Sales and Marketing Officer and Director
|
|
August 1988
|
Moshe Citronowicz
|
|
65
|
|
Senior Vice President
|
|
N/A
|
Andrew Makrides
|
|
76
|
|
Chairman of the Board
|
|
December 1982
|
Lawrence J. Waldman
|
|
71
|
|
Director
|
|
March 2011
|
Michael Geraghty
|
|
71
|
|
Director
|
|
March 2011
|
John Andres
|
|
60
|
|
Vice-Chairman of the Board
|
|
July 2014
|
•
|
Executive sessions without management and non-independent directors present are a standing Board agenda item. Executive sessions of the independent directors are held at any time requested by an independent director and, in any event, are held in connection with at least 100% of regularly scheduled Board meetings.
|
•
|
The Board regularly meets in executive session with the CEO without other members of management present.
|
•
|
All Board committee members are independent directors. The committee chairs have authority to hold executive sessions without management and non-independent directors present.
|
Avinger, Inc.
|
Esko Bionics Holdings, Inc.
|
IRIDEX Corporation
|
AxoGen, Inc.
|
Fonar Corporation
|
Misonix, Inc.
|
BIOLASE, Inc
|
iCAD, Inc.
|
Retractable Technologies, Inc.
|
Cogentix Medical, Inc.
|
Invuity, Inc.
|
Utah Medical Products Inc.
|
Cutera, Inc.
|
IRadimed Corporation
|
|
(In millions)
|
|
Threshold
|
|
Target
|
|
Achievement
|
|
Overall Weight
|
|
Achievement
|
|
Calculation
|
||||||
Advanced Energy Revenue
|
|
5.1
|
|
|
6.8
|
|
|
7.6
|
|
|
30
|
%
|
|
125
|
%
|
|
37.5
|
%
|
Core Revenue
|
|
27.0
|
|
|
30.0
|
|
|
28.6
|
|
|
10
|
%
|
|
75
|
%
|
|
7.5
|
%
|
OEM Revenue
|
|
3.7
|
|
|
4.1
|
|
|
2.6
|
|
|
10
|
%
|
|
—
|
%
|
|
—
|
%
|
Operating Loss
|
|
(3.1
|
)
|
|
(2.75
|
)
|
|
(5.2
|
)
|
|
25
|
%
|
|
—
|
%
|
|
—
|
%
|
Total Cash Balance
|
|
7.2
|
|
|
9.6
|
|
|
9.9
|
|
|
10
|
%
|
|
110
|
%
|
|
11.0
|
%
|
MBO
|
|
1
|
|
|
1
|
|
|
1
|
|
|
15
|
%
|
|
100
|
%
|
|
15.0
|
%
|
Total
|
|
|
|
|
|
|
|
100
|
%
|
|
|
|
71.0
|
%
|
Name
|
|
Bonus
|
|
||
Charles D. Goodwin
|
|
$
|
—
|
|
|
Jay D. Ewers
|
|
$
|
67,344
|
|
*
|
J. Robert Saron
|
|
$
|
83,119
|
|
*
|
Moshe Citronowicz
|
|
$
|
56,263
|
|
*
|
Robert L. Gershon
|
|
$
|
122,080
|
|
|
Jack McCarthy
|
|
$
|
59,191
|
|
|
Total
|
|
$
|
387,997
|
|
|
|
|||||||||||||||||||||||||||||||||
Name and Principal Position
|
|
Year
|
|
Salary
|
|
Bonus
($) |
|
Stock Awards
($) |
|
Option Awards
($) (1) |
|
Non-Equity Incentive Plan Compensation Earnings
($) |
|
Change in Pension Value and Nonqualified Deferred Compensation Earnings
($) |
|
All Other Compensation
($) (7) |
|
Total
($) |
|||||||||||||||
Charles D. Goodwin
|
|
2017
|
|
$
|
15,385
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
15,385
|
|
CEO and Director
|
|
2016
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
2015
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Jay D. Ewers*
|
|
2017
|
|
$
|
271,000
|
|
|
$
|
300
|
|
(2)
|
$
|
—
|
|
|
137,340
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
8,491
|
|
|
$
|
417,131
|
|
Chief Financial Officer,
|
|
2016
|
|
$
|
235,000
|
|
|
$
|
109,892
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
10,608
|
|
|
$
|
355,500
|
|
Treasurer and Secretary
|
|
2015
|
|
$
|
171,456
|
|
|
$
|
65,255
|
|
|
$
|
—
|
|
|
70,655
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
32,185
|
|
|
$
|
339,551
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
J. Robert Saron
|
|
2017
|
|
$
|
334,485
|
|
|
$
|
300
|
|
(3)
|
$
|
—
|
|
|
137,340
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
19,769
|
|
|
$
|
491,894
|
|
President, Chief Sales &
|
|
2016
|
|
$
|
318,917
|
|
|
$
|
148,956
|
|
|
$
|
—
|
|
|
32,375
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
24,383
|
|
|
$
|
524,631
|
|
Marketing Officer & Director
|
|
2015
|
|
$
|
305,184
|
|
|
$
|
79,543
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
24,383
|
|
|
$
|
409,110
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Moshe Citronowicz
|
|
2017
|
|
$
|
226,410
|
|
|
$
|
300
|
|
(4)
|
$
|
—
|
|
|
137,340
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
18,968
|
|
|
$
|
383,018
|
|
Senior Vice President
|
|
2016
|
|
$
|
213,990
|
|
|
$
|
100,112
|
|
|
$
|
—
|
|
|
32,375
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
22,066
|
|
|
$
|
368,543
|
|
|
|
2015
|
|
$
|
204,775
|
|
|
$
|
53,537
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
22,066
|
|
|
$
|
280,378
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Robert L. Gershon
|
|
2017
|
|
$
|
436,000
|
|
|
$
|
122,080
|
|
|
$
|
—
|
|
|
196,200
|
|
(5)
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
29,367
|
|
|
$
|
783,647
|
|
CEO and Director
|
|
2016
|
|
$
|
365,750
|
|
|
$
|
293,724
|
|
|
$
|
—
|
|
|
65,625
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
30,201
|
|
|
$
|
755,300
|
|
|
|
2015
|
|
$
|
350,000
|
|
|
$
|
180,000
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
30,201
|
|
|
$
|
560,201
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Jack McCarthy
|
|
2017
|
|
$
|
287,375
|
|
|
$
|
59,191
|
|
|
$
|
—
|
|
|
137,340
|
|
(6)
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
27,242
|
|
|
$
|
511,148
|
|
Chief Commercialization
|
|
2016
|
|
$
|
287,375
|
|
|
$
|
134,273
|
|
|
$
|
—
|
|
|
32,375
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
29,922
|
|
|
$
|
483,945
|
|
Officer
|
|
2015
|
|
$
|
275,000
|
|
|
$
|
74,500
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
29,922
|
|
|
$
|
379,422
|
|
(1)
|
These columns represent the grant date fair value of the awards as calculated in accordance with FASB ASC 718 (Stock Compensation). Pursuant to SEC rule changes effective February 28, 2010, we are required to reflect the total grant date fair values of the option grants in the year of grant, rather than the portion of this amount that was recognized for financial statement reporting purposes in a given fiscal year which was required under the prior SEC rules, resulting in a change to the amounts reported in prior Annual Reports.
|
(2)
|
The Company and Mr. Ewers voluntarily agreed to waive his bonus payment for 2017 of $67,344.
|
(3)
|
The Company and Mr. Saron voluntarily agreed to waive his bonus payment for 20177 of $83,119.
|
(4)
|
The Company and Mr. Citronowicz voluntarily agreed to waive his bonus payment for 2017 of $56,263.
|
(5)
|
Mr. Gershon resigned from all of his positions with the Company effective December 15, 2017. In connection with this departure, unvested options were forfeited in accordance with the terms of the Separation Agreement.
|
(6)
|
Mr. McCarthy was terminated without cause from his position with the Company effective November 6, 2017. In connection with this departure, unvested options were forfeited pursuant to the terms of his employment contract and the option agreements.
|
(7)
|
The amounts for
2017
include compensation under the following plans and programs:
|
|
|
C.D.
Goodwin |
|
J.D.
Ewers |
|
J.R.
Saron |
|
M.
Citronowicz |
|
R.L.
Gershon |
|
J.J.
McCarthy |
||||||||||||
Life insurance premiums
|
|
—
|
|
|
425
|
|
|
499
|
|
|
464
|
|
|
502
|
|
|
502
|
|
||||||
Health insurance premiums
|
|
—
|
|
|
—
|
|
|
11,170
|
|
|
11,775
|
|
|
20,765
|
|
|
21,927
|
|
||||||
Employer 401(k) contribution
|
|
—
|
|
|
8,066
|
|
|
8,100
|
|
|
6,729
|
|
|
8,100
|
|
|
4,813
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Total
|
|
$
|
—
|
|
|
$
|
8,491
|
|
|
$
|
19,769
|
|
|
$
|
18,968
|
|
|
$
|
29,367
|
|
|
$
|
27,242
|
|
Name
|
|
Contract Expiration Date
|
Charles D. Goodwin
|
|
N/A
(1)
|
Jay D. Ewers
|
|
N/A
(1)
|
J. Robert Saron
|
|
December 31, 2018
|
Moshe Citronowicz
|
|
December 31, 2018
|
(1)
|
Employment contracts provide for the Executives to remain employed by the Company until such time as their employment is terminated pursuant to the terms of their Employment Agreement.
|
(a)
|
Upon the death of the executive, in which case the executive’s estate shall be paid the basic annual compensation due the employee pro-rated through the date of death.
|
(b)
|
By the resignation of the executive at any time upon at least thirty (30) days prior written notice to Bovie in which case Bovie shall be obligated to pay the employee the basic annual compensation due him pro-rated to the effective date of termination.
|
(c)
|
By Bovie, “for cause” if during the term of the employment agreement the employee violates the non-competition provisions of his employment agreement, or is found guilty in a court of law of any crime of moral turpitude in which case the contract would be terminated and provisions for future compensation forfeited.
|
(d)
|
By Bovie, without cause, with the majority approval of the Board of Directors, for Mr. Goodwin, Mr. Saron, Mr. Ewers and Mr. Citronowicz at any time upon at least thirty (30) days prior written notice to the executive. In this case Bovie shall be obligated to pay the executive compensation in effect at such time, including all bonuses, accrued or prorated and expenses up to the date of termination. Thereafter for Messrs. Saron and Citronowicz, Bovie shall pay the executive three times the salary in effect at the time of termination payable in one lump sum.
|
(e)
|
If Bovie fails to meet its obligations to the executive on a timely basis, or if there is a change in the control of Bovie, the executive may elect to terminate his employment agreement. Upon any such termination or breach of any of its obligations under the employment agreement, Bovie shall pay Mr. Saron and Mr. Citronowicz a lump sum severance equal to three times the annual salary and bonus in effect the month preceding such termination or breach as well as any other sums which may be due under the terms of the employment agreement up to the date of termination. Mr. Goodwin and Mr. Ewers shall be paid two times their annual salary and bonus in effect the month preceding such termination or breach as well as any other sums which may be due under the terms of their respective employment agreement up to the date of termination.
|
Name
|
|
# of Securities
Underlying
Unexercised
Options
(# Exercisable)
|
|
# of Securities Underlying Unexercised Options
(# Unexercisable)
|
|
Weighted Average Option
Exercise Price
($/Sh)
|
|
Option Expiration
Range After Grant Date
|
||||||
Charles D. Goodwin
|
|
—
|
|
|
1,000,000
|
|
|
$
|
2.99
|
|
|
12/15/2027
|
||
Jay D. Ewers
|
|
58,750
|
|
|
141,250
|
|
|
$
|
2.85
|
|
|
6/30/2024
|
-
|
1/4/2028
|
J. Robert Saron
|
|
39,250
|
|
|
97,750
|
|
|
$
|
2.69
|
|
|
7/12/2022
|
-
|
5/1/2027
|
Moshe Citronowicz
|
|
39,250
|
|
|
97,750
|
|
|
$
|
2.69
|
|
|
7/12/2022
|
-
|
5/1/2027
|
Name (a)
|
|
Fees Earned Or Paid In Cash
($) (b) |
|
Stock Awards ($)
(c) |
|
Option Awards
*** ($) (d)(1) |
|
Non-Equity Incentive Plan Compensation
($) (e) |
|
Change in Pension Value and Nonqualified Deferred Compensation Earnings
($) (I) |
|
All Other Compensation
($) (g) |
|
Total
($) (h) |
||||||||||||||
Andrew Makrides
|
|
$
|
50,000
|
|
|
$
|
—
|
|
|
$
|
20,772
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
70,772
|
|
Lawrence J. Waldman
|
|
$
|
70,000
|
|
|
$
|
—
|
|
|
$
|
20,772
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
90,772
|
|
Michael Geraghty
|
|
$
|
40,000
|
|
|
$
|
—
|
|
|
$
|
20,772
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
60,772
|
|
John Andres
|
|
$
|
66,500
|
|
|
$
|
—
|
|
|
$
|
20,772
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
87,272
|
|
(1)
|
On September 14, 2017, 12,000 one year stock options with an exercise price of $2.85 and calculated option fair value of $1.731 were granted to each member of the Board.
|
|
|
Number of Shares
|
|
|
|
|
|
||||
Name and Address
|
|
Title
|
|
Owned (i)
|
|
|
Nature of Ownership
|
|
Percentage of Ownership (i)
|
||
William Weeks Vanderfelt
|
|
Common
|
|
2,417,899
|
|
|
|
Beneficial
|
|
7.3
|
%
|
Coralis 44, Azzuri Village 44
|
|
|
|
|
|
|
|
|
|
||
Roches Noires, 31201 Mauritius
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
Archon Capital Management, LLC
|
|
Common
|
|
2,158,538
|
|
|
|
Beneficial
|
|
6.5
|
%
|
1100 19th Avenue E
|
|
|
|
|
|
|
|
|
|
||
Seattle, WA 98122
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
RTW Investments
|
|
Common
|
|
1,752,611
|
|
|
|
Beneficial
|
|
5.3
|
%
|
250 West 55th St. 16th Floor
|
|
|
|
|
|
|
|
|
|
||
New York, NY 10019
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
Andrew Makrides
|
|
Common
|
|
641,972
|
|
(ii)
|
|
Beneficial
|
|
1.9
|
%
|
5115 Ulmerton Rd.
|
|
|
|
|
|
|
|
|
|
||
Clearwater, FL 33760
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
Charles D. Goodwin II
|
|
Common
|
|
—
|
|
(iii)
|
|
Beneficial
|
|
—
|
%
|
5115 Ulmerton Rd.
|
|
|
|
|
|
|
|
|
|
||
Clearwater, FL 33760
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
J. Robert Saron
|
|
Common
|
|
445,190
|
|
(iv)
|
|
Beneficial
|
|
1.3
|
%
|
5115 Ulmerton Rd.
|
|
|
|
|
|
|
|
|
|
||
Clearwater, FL 33760
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
Moshe Citronowicz
|
|
Common
|
|
465,754
|
|
(v)
|
|
Beneficial
|
|
1.4
|
%
|
5115 Ulmerton Rd.
|
|
|
|
|
|
|
|
|
|
||
Clearwater, FL 33760
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
John Andres
|
|
Common
|
|
34,500
|
|
(vi)
|
|
Beneficial
|
|
0.1
|
%
|
5115 Ulmerton Rd.
|
|
|
|
|
|
|
|
|
|
||
Clearwater, FL 33760
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
Jay D. Ewers
|
|
Common
|
|
58,750
|
|
(vii)
|
|
Beneficial
|
|
0.2
|
%
|
5115 Ulmerton Rd.
|
|
|
|
|
|
|
|
|
|
||
Clearwater, FL 33760
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
Michael E. Geraghty
|
|
Common
|
|
62,000
|
|
(viii)
|
|
Beneficial
|
|
0.2
|
%
|
5115 Ulmerton Rd.
|
|
|
|
|
|
|
|
|
|
||
Clearwater, FL 33760
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
Lawrence Waldman
|
|
Common
|
|
113,000
|
|
(ix)
|
|
Beneficial
|
|
0.3
|
%
|
5115 Ulmerton Rd.
|
|
|
|
|
|
|
|
|
|
||
Clearwater, FL 33760
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
Officers and Directors as a group (8 persons)
|
|
|
|
1,821,166
|
|
(x)
|
|
|
|
5.5
|
%
|
(i)
|
Based on 33,021,170 outstanding shares of Common Stock and 4,890,156 outstanding options to acquire a like number of shares of Common Stock as of March 5, 2018, of which officers and directors owned a total of 376,750 options and 1,444,416 shares at March 5, 2018. We have calculated the percentage on the basis of the amount of outstanding securities plus, for each person or group, any securities that person or group has current or future right to acquire pursuant to options, warrants, conversion privileges or other rights.
|
(ii)
|
Includes 611,972 shares and 30,000 vested options out of a total of 30,000 ten year options owned by Mr. Makrides to purchase shares of Common Stock of the Company at an exercise price of $2.54. These options vest equally over a four year period.
|
(iii)
|
Includes 0 shares and 0 vested options out of a total of 1,000,000 ten year options owned by Mr. Goodwin to purchase shares of Common Stock of the Company. Exercise price for his options is $2.99. These options vest equally over a two year period.
|
(iv)
|
Includes 405,940 shares and 39,250 vested options out of a total of 137,000 ten year options owned by Mr. Saron to purchase shares of Common Stock of the Company at an exercise price ranging from $1.80 to $3.23. These options vest equally over a four year period.
|
(v)
|
Includes 426,504 shares and 39,250 vested options out of a total of 137,000 ten year options owned by Mr. Citronowicz to purchase shares of Common Stock of the Company at an exercise price ranging from $1.80 to $3.23. These options vest equally over a four year period.
|
(vi)
|
Includes 34,500 vested options out of a total of 46,500 ten year options owned by Mr. Andres to purchase shares of Common Stock of the Company at an exercise price ranging from $1.88 to $3.81
|
(vii)
|
Includes 58,750 vested options out of a total of 200,000 ten year options owned by Mr. Ewers to purchase shares of Common Stock of the Company at an exercise price ranging from $2.13 to $3.63. These options vest equally over a four year period.
|
(viii)
|
Includes 62,000 vested options out of a total of 74,000 ten year options owned by Mr. Geraghty to purchase shares of Common Stock of the Company at an exercise price ranging from $1.88 to $3.81
|
(ix)
|
Includes 113,000 vested options out of a total of 125,000 ten year options owned by Mr. Waldman to purchase shares of Common Stock of the Company at an exercise price ranging from $1.88 to $3.81
|
(x)
|
Includes 376,750 vested ten year options out of a total of 1,761,500 ten year outstanding options and 1,444,416 shares owned by all Executive Officers and directors as a group. The last date options can be exercised is January 4, 2028.
|
|
Year Ended December 31,
|
||||||
(In thousands)
|
2017
|
|
2016
|
||||
Audit fees
(1)
|
$
|
194
|
|
|
$
|
173
|
|
Non-Audit fees:
|
|
|
|
||||
Audit related fees
(2)
|
4
|
|
|
3
|
|
||
Tax fees
(3)
|
—
|
|
|
—
|
|
||
All other fees
(4)
|
—
|
|
|
—
|
|
||
Total fees billed
|
$
|
198
|
|
|
$
|
176
|
|
(1)
|
Audit fees consist of fees billed for professional services rendered for the audit of Bovie’s annual financial statements and reviews of its interim consolidated financial statements included in quarterly reports and other services related to statutory and regulatory filings or engagements.
|
(2)
|
Audit related fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit or reviews of Bovie’s consolidated financial statements and are not reported under “Audit Fees”.
|
(3)
|
Tax fees consist of fees billed for professional services rendered for tax compliance and tax advice (domestic and international). These services include assistance regarding federal, state and international tax compliance, acquisitions and international tax planning.
|
(4)
|
All other fees consist of fees for products and services other than the services reported above.
|
(a)(1)
|
LISTING OF FINANCIAL STATEMENTS
|
Page
|
||
|
|
|
|
|
|
The following consolidated financial statements of the Company are included in Item 8 of this Report:
|
|
||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
(a)(2)
|
FINANCIAL STATEMENT SCHEDULES
|
|
||
|
|
All financial statement schedules have been omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and notes thereto included in this Report.
|
|
1.1
|
|
|
1.2
|
|
|
3.1
|
|
|
3.2
|
|
|
3.3
|
|
|
3.4
|
|
|
10.1
|
|
|
10.2
|
|
|
10.3
|
|
|
10.4
|
|
|
10.5
|
|
|
10.6
|
|
|
10.7
|
|
|
10.8
|
|
|
10.9
|
|
|
10.10
|
|
10.11
|
|
|
10.12
|
|
|
10.13
|
|
|
10.14
|
|
|
10.15
|
|
|
10.16*
|
|
|
10.17*
|
|
|
14.1
|
|
|
21.1*
|
|
|
23.1*
|
|
|
31.1*
|
|
|
31.2*
|
|
|
32.1*
|
|
|
32.2*
|
|
|
101.INS**
|
|
XBRL Instance Document
|
101.SCH**
|
|
XBRL Taxonomy Extension Schema Document
|
101.CAL**
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
101.DEF**
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
101.LAB**
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
101.PRE**
|
|
XBRL Taxonomy Extension Label Presentation Document
|
|
Bovie Medical Corporation
|
|
|
|
|
|
|
|
By:
|
/s/ Charles D. Goodwin II
|
|
|
|
Charles D. Goodwin II
|
|
|
|
Chief Executive Officer and Director
|
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
By:
|
/s/ Jay D. Ewers
|
|
|
|
Jay D. Ewers
|
|
|
|
Chief Financial Officer,
|
|
|
|
Treasurer and Secretary
|
|
|
|
(Principal Financial Officer)
|
|
Name
|
|
Title
|
|
Date
|
|
|
|
|
|
Directors:
|
|
|
|
|
|
|
|
|
|
/s/ ANDREW MAKRIDES
|
|
Chairman of the Board
|
|
March 13, 2018
|
Andrew Makrides
|
|
|
|
|
|
|
|
|
|
/s/ CHARLES D. GOODWIN II
|
|
Chief Executive Officer and Director
|
|
March 13, 2018
|
Charles D. Goodwin II
|
|
|
|
|
|
|
|
|
|
/s/ JAY D. EWERS
|
|
Chief Financial Officer, Treasurer and Secretary
|
|
March 13, 2018
|
Jay D. Ewers
|
|
|
|
|
|
|
|
|
|
/s/ J. ROBERT SARON
|
|
President, Chief Sales and Marketing Officer and Director
|
|
March 13, 2018
|
J. Robert Saron
|
|
|
|
|
|
|
|
|
|
/s/ JOHN ANDRES
|
|
Vice Chairman of the Board
|
|
March 13, 2018
|
John Andres
|
|
|
|
|
|
|
|
|
|
/s/ LAWRENCE J. WALDMAN
|
|
Director
|
|
March 13, 2018
|
Lawrence J. Waldman
|
|
|
|
|
|
|
|
|
|
/s/ MICHAEL GERAGHTY
|
|
Director
|
|
March 13, 2018
|
Michael Geraghty
|
|
|
|
|
1 Year Bovie Chart |
1 Month Bovie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions